Wu-tou decoction (WTD) is a classic traditional Chinese medicine formula and has been extensively used for the treatment of rheumatoid arthritis (RA). Previous reports indicate that WTD possesses anti-inflammatory and antinociceptive activities, and inhibits the development of arthritic joints and disease severity of collagen-induced arthritis (CIA) or adjuvant-induced rats; however, its action on angiogenesis of RA has not been clarified. This study aims to determine the anti-angiogenic activity of WTD in CIA rats and in various angiogenesis models. Our data showed that WTD (0.95, 1.9, and 3.8 g/kg) markedly reduced the immature blood vessels in synovial membrane tissues of inflamed joints from CIA rats. It also inhibited in vivo angiogenesis in chick embryo and VEGF165-induced microvessel sprout formation ex vivo. Meanwhile, WTD suppressed VEGF165-/MH7A-induced migration, invasion, adhesion, and tube formation of human umbilical vein endothelial cells (HUVECs). Moreover, WTD significantly reduced the expression of angiogenic activators, including vascular endothelial growth factor (VEGF), VEGFR2, interleukin (IL)-1β, IL-17, transforming growth factor-β, platelet-derived growth factor, placenta growth factor, angiopoietin (Ang) I and Ang II in synovium of CIA rats, and/or in HUVECs. More interestingly, WTD blocked the autophosphorylation of VEGF165-induced VEGFR2 and consequently downregulated the signaling pathways of activated AKT, ERK1/2, JNK, and p38 in VEGF165-induced HUVECs. These findings suggest for the first time that WTD possesses the anti-angiogenic effect in RA in vivo, ex vivo, and in vitro by interrupting the targeting of VEGFR2 activation.
Get full access to this article
View all access options for this article.
References
1.
JoshiVR. Arthritis in the elderly. J Indian Med Assoc, 2003; 101:408, 410, 412 passim.
2.
SymmonsDP, BarrettEM, BankheadCR, ScottDG, SilmanAJ. The incidence of rheumatoid arthritis in the United Kingdom: Results from the Norfolk Arthritis Register. Br J Rheumatol, 1994; 33:735–739.
3.
TasSW, MaracleCX, BaloghE, SzekaneczZ. Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol, 2016; 12:111–122.
4.
ThairuN, KiriakidisS, DawsonP, PaleologE. Angiogenesis as a therapeutic target in arthritis in 2011: Learning the lessons of the colorectal cancer experience. Angiogenesis, 2011; 14:223–234.
5.
MarrelliA, CiprianiP, LiakouliV, CarubbiF, PerriconeC, PerriconeR, GiacomelliR. Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. Autoimmun Rev, 2011; 10:595–598.
6.
SemeranoL, ClavelG, AssierE, DenysA, BoissierMC. Blood vessels, a potential therapeutic target in rheumatoid arthritis?. Joint Bone Spine, 2011; 78:118–123.
7.
VealeDJ, FearonU. Inhibition of angiogenic pathways in rheumatoid arthritis: Potential for therapeutic targeting. Best Pract Res Clin Rheumatol, 2006; 20:941–947.
8.
NeufeldG, CohenT, GengrinovitchS, PoltorakZ. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 1999; 13:9–22.
9.
ElshabrawyHA, ChenZ, VolinMV, RavellaS, VirupannavarS, ShahraraS. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis, 2015; 18:433–448.
10.
SzekaneczZ, KochAE. Angiogenesis and its targeting in rheumatoid arthritis. Vasc Pharmacol, 2009; 51:1–7.
11.
SzekaneczZ, BesenyeiT, ParaghG, KochAE. New insights in synovial angiogenesis. Joint Bone Spine, 2010; 77:13–19.
PanR, DaiY, GaoXH, LuD, XiaYF. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways. Vascul Pharmacol, 2011; 54:18–28.
14.
ZhuX, OkuboA, IgariN, NinomiyaK, EgashiraY. Modified rice bran hemicellulose inhibits vascular endothelial growth factor-induced angiogenesis in vitro via VEGFR2 and its downstream signaling pathways. Biosci Microbiota Food Health, 2017; 36:45–53.
15.
WangC, LiuC, WanH, WangD, SunD, XuT, YangY, QuY, XuY, JingX, LiuJ, ChenS, LiuZ, LinN. Wu-tou decoction inhibits chronic inflammatory pain in mice: Participation of TRPV1 and TRPA1 ion channels. Biomed Res Int, 2015; 2015:328707.
16.
GuoQ, ZhengK, FanD, ZhaoY, LiL, BianY, QiuX, LiuX, ZhangG, MaC, HeX, LuA. Wu-Tou decoction in rheumatoid arthritis: Integrating network pharmacology and in vivo pharmacological evaluation. Front Pharmacol, 2017; 8:230.
17.
ZhangY, MaoX, GuoQ, BaiM, ZhangB, LiuC, SunY, LiS, LinN. Pathway of PPAR-gamma coactivators in thermogenesis: A pivotal traditional Chinese medicine-associated target for individualized treatment of rheumatoid arthritis. Oncotarget, 2016; 7:15885–15900.
18.
ZhangY, BaiM, ZhangB, LiuC, GuoQ, SunY, WangD, WangC, JiangY, LinN, LiS. Uncovering pharmacological mechanisms of Wu-tou decoction acting on rheumatoid arthritis through systems approaches: Drug-target prediction, network analysis and experimental validation. Sci Rep, 2015; 5:9463.
19.
QiY, LiS, PiZ, SongF, LinN, LiuS, LiuZ. Metabonomic study of Wu-tou decoction in adjuvant-induced arthritis rat using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2014; 953–954:11–19.
20.
RemmersEF, JoeB, GriffithsMM, DobbinsDE, DrachevaSV, HashiramotoA, FuruyaT, SalstromJL, WangJ, GulkoPS, CannonGW, WilderRL. Modulation of multiple experimental arthritis models by collagen-induced arthritis quantitative trait loci isolated in congenic rat lines: Different effects of non-major histocompatibility complex quantitative trait loci in males and females. Arthritis Rheum, 2002; 46:2225–2234.
21.
BrennerM, MengHC, YarlettNC, GriffithsMM, RemmersEF, WilderRL, GulkoPS. The non-MHC quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation and joint damage. Arthritis Rheum, 2005; 52:322–332.
22.
MouldAW, TonksID, CahillMM, PettitAR, ThomasR, HaywardNK, KayGF. LVegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum, 2003; 48:2660–2669.
23.
IzquierdoE, CañeteJD, CelisR, SantiagoB, UsateguiA, SanmartíR, Del ReyMJ, PablosJL. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One, 2009; 4:e8131.
HaasCS, AminMA, AllenBB, RuthJH, HainesGK3rd, WoodsJM, KochAE. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum, 2006; 54:2402–2414.
27.
KokTW, YuePY, MakNK, FanTP, LiuL, WongRN. The anti-angiogenic effect of sinomenine. Angiogenesis, 2005; 8:3–12.
28.
StrieterRM, PolveriniPJ, KunkelSL, ArenbergDA, BurdickMD, KasperJ, DzuibaJ, Van DammeJ, WalzA, MarriottD. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem, 1995; 270:27348–27357.
HanDO, LeeHJ, HahmDH. Wound-healing activity of Astragali Radix in rats. Methods Find Exp Clin Pharmacol, 2009; 31:95–100.
31.
ZhangY, HuG, LiS, LiZH, LamCO, HongSJ, KwanYW, ChanSW, LeungGP, LeeSM. Pro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo. Mol Med Rep, 2012; 5:805–811.
32.
HuG, MahadyGB, LiS, HoiMP, WangYH, LeeSM. Polysaccharides from astragali radix restore chemical-induced blood vessel loss in zebrafish. Vasc Cell, 2012; 4:2.
33.
JungY, JerngU, LeeS. A systematic review of anticancer effects of radix astragali. Chin J Integr Med, 2016; 22:225–236.
34.
LawPC, AuyeungKK, ChanLY, KoJK. Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells. BMC Complement Altern Med, 2012; 12:160.
35.
PotenteM, GerhardtH, CarmelietP. Basic and therapeutic aspects of angiogenesis. Cell, 2011; 146:873–887.
36.
MaeshimaY, SudhakarA, LivelyJC, UekiK, KharbandaS, KahnCR, SonenbergN, HynesRO, KalluriR. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science, 2002; 295:140–143.
37.
LiH, ShiX, LiuJ, HuC, ZhangX, LiuH, JinJ, OpolonP, VannierJP, PerricaudetM, JaninA, SoriaC, LuH. The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation. Cancer Gene Ther, 2010; 17:700–707.
38.
XueL, ZhangHY, QinL, WangXC, WangL. Effect of chuanwu and baishao used separately or in combination on adjuvant arthritis in rats. Zhongguo Zhong Yao Za Zhi, 2000; 25:175–178.
FuY, ChenJ, LiYJ, ZhengYF, LiP. Antioxidant and anti-inflammatory activities of six flavonoids separated from licorice. Food Chem, 2013; 141:1063–1071.
41.
HikinoH, KonnoC, TakataH, TamadaM. Antiinflammatory principle of Ephedra Herbs. Chem Pharm Bull (Tokyo), 1980; 28:2900–2904.
42.
KimIS, ParkYJ, YoonSJ, LeeHB. Ephedrannin A and B from roots of Ephedra sinica inhibit lipopolysaccharide-induced inflammatory mediators by suppressing nuclear factor-κB activation in RAW 264.7 macrophages. Int Immunopharmacol, 2010; 10:1616–1625.
43.
BiX, HanL, QuT, MuY, GuanP, QuX, WangZ, HuangX. Anti-inflammatory effects, SAR, and action mechanism of monoterpenoids from radix paeoniae Alba on LPS-stimulated RAW 264.7 cells. Molecules, 2017; 22:pii: E715.
44.
RyuM, KimEH, ChunM, KangS, ShimB, YuYB, JeongG, LeeJS. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk. J Ethnopharmacol, 2008; 115:184–193.
45.
PickensSR, VolinMV, MandelinAM2nd, KollsJK, PopeRM, ShahraraS. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol, 2010; 184:3233–3241.
46.
GuadagniF, FerroniP, PalmirottaR, PortarenaI, FormicaV, RoselliM. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: An early target in anticancer therapeutic strategy. In Vivo, 2007; 21:147–161.
47.
BottomleyMJ, WebbNJ, WatsonCJ, HoltPJ, FreemontAJ, BrenchleyPE. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol, 1999; 117:171–176.
48.
GerhardtH, SembH. Pericytes: Gatekeepers in tumour cell metastasis?. J Mol Med (Berl), 2008; 86:135–144.
49.
KaramyshevaAF. Mechanisms of angiogenesis. Biochemistry (Mosc), 2008; 73:751–762.
GreenbergJI, ShieldsDJ, BarillasSG, AcevedoLM, MurphyE, HuangJ, ScheppkeL, StockmannC, JohnsonRS, AngleN. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature, 2008; 456:809–813.
52.
MuzB, LarsenH, MaddenL, KiriakidisS, PaleologEM. Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis. Arthritis Rheum, 2012; 64:2856–2867.
YiT, YiZ, ChoSG, LuoJ, PandeyMK, AggarwalBB, LiuM. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res, 2008; 68:1843–1850.
55.
LinC, WuM, DongJ. Quercetin-4 '-O-beta-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells. PLoS One, 2012; 7:e31708.
56.
LiangX, XuF, LiX, MaC, ZhangY, XuW. VEGF signal system: The application of antiangiogenesis. Curr Med Chem, 2014; 21:894–910.
57.
DengQ, BaiS, GaoW, TongL. Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways. Int Immunopharmacol, 2015; 29:302–313.
58.
GaoWei, SweeneyCatherine, WalshCeara, RooneyPeadar, McCormickJennifer, VealeDouglas J, FearonUrsula. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann Rheum Dis, 2013; 72:1080–1088.
59.
MaracleChrissta X., KucharzewskaPaulina, HelderBoy, van der HorstCorine, de SampaioPedro Correa, NoortAe-Ri, van ZoestKatinka, GriffioenArjan W, OlssonHenric, TasSander W.. Targeting non-canonical nuclear factor-iB signaling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis. Rheumatology (Oxford), 2017; 56:294–302.
